Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu srovnávací studie, hodnotící studie, časopisecké články, práce podpořená grantem
PubMed
24246692
DOI
10.1016/j.leukres.2013.10.019
PII: S0145-2126(13)00374-3
Knihovny.cz E-zdroje
- Klíčová slova
- Chronic lymphocytic leukemia, Clonal evolution, CpG oligonucleotides, Cytogenetics, Fluorescence in situ hybridization, Interleukin-2,
- MeSH
- aktivace lymfocytů účinky léků MeSH
- chronická lymfatická leukemie genetika patologie MeSH
- dospělí MeSH
- hybridizace in situ fluorescenční * MeSH
- interleukin-2 farmakologie MeSH
- klonální evoluce * MeSH
- lidé středního věku MeSH
- lidé MeSH
- oligodeoxyribonukleotidy farmakologie MeSH
- prospektivní studie MeSH
- pruhování chromozomů * MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- hodnotící studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- CPG-oligonucleotide MeSH Prohlížeč
- interleukin-2 MeSH
- oligodeoxyribonukleotidy MeSH
Chronic lymphocytic leukemia (CLL) patients may acquire new chromosome abnormalities during the course of their disease. Clonal evolution (CE) has been detected by conventional chromosome banding (CBA), several groups also confirmed CE with fluorescence in situ hybridization (FISH). At present, there are minimal prospective data on CE frequency determined using a combination of both methods. Therefore, the aim of our study was to prospectively assess CE frequency using a combination of FISH and CBA after stimulation with CpG oligonucleotides and interleukin-2. Between 2008 and 2012, we enrolled 140 patients with previously untreated CLL in a prospective trial evaluating CE using FISH and CBA after stimulation. Patients provided baseline and regular follow-up peripheral blood samples for testing. There was a median of 3 cytogenetic examinations (using both methods) per patient. CE was detected in 15.7% (22/140) of patients using FISH, in 28.6% (40/140) using CBA, and in 34.3% (48/140) of patients by combining both methods. Poor-prognosis CE (new deletion 17p, new deletion 11q or new complex karyotype) was detected in 15% (21/140) of patients and was significantly associated with previous CLL treatment (p=0.013). CBA provides more complex information about cytogenetic abnormalities in CLL patients than FISH and confirms that many patients can acquire new abnormalities during the course of their disease in a relatively short time period.
Citace poskytuje Crossref.org